Skip to main content

Table 1 Patient demographics, and disease and concomitant treatment characteristics

From: The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia

Characteristic

Total evaluable patients

(N = 224)

Age, years, mean (SD)

45.3 (13.45)

Males, n (%)

160 (71.4)

Family status, single, n (%); n = 222

144 (64.9)

Living arrangement, n (%)

 Alone

65 (29.0)

 With family (parents/siblings)

97 (43.3)

 With partner/children

42 (18.8)

 Other

20 (8.8)

In education/employment, yes, n (%)

54 (24.3)a

 Student

7 (3.2)

 Employed (paid, voluntary, self-employed)

46 (20.8)

Country, n (%)

 Belgium

4 (1.8)

 France

63 (28.1)

 Germany

6 (2.7)

 Hungary

23 (10.3)

 Italy

37 (16.5)

 Spain

84 (37.5)

 United Kingdom

7 (3.1)

Patients receiving other non-pharmacological treatments or care currently, yes (%); n = 218

96 (44.0)

Years living with schizophrenia diagnosis, mean (SD); n = 214

12.0 (10.15)

Years taking antipsychotic medication, mean (SD); n = 211

12.1 (9.69)

EQ-5D-5L VAS, mean (SD); n = 190b

70.8 (19.60)

CGI-Severity score, mean (SD); n = 221

3.7 (0.99)

CGI-Severity categories,c n (%); n = 221

 Normal, not at all ill

5 (2.3)

 Borderline mentally ill

17 (7.7)

 Mildly ill

60 (27.1)

 Moderately ill

101 (45.7)

 Markedly ill

31 (14.0)

 Severely ill

7 (3.2)

PANSS item G12 lack of judgement and insight, mean (SD); n = 212

3.2 (1.30)

PANSS item G12 lack of judgement and insight categories, n (%);d n = 212

 Absent

19 (9.0)

 Minimal

38 (17.9)

 Mild

77 (36.3)

 Moderate

44 (20.8)

 Moderate severe

20 (9.4)

 Severe

13 (6.1)

 Extreme

1 (0.5)

Current psychiatric comorbidities, yes, n (%);e n = 222

59 (26.6)

Other concomitant psychotropic treatments currently prescribed in addition to PP3M, yes, n (%);f n = 221

139 (62.9)

 Oral antipsychotic

78 (35.3)

 Anxiolytic/hypnotic

77 (34.8)

 Anticholinergic

18 (8.1)

 Antidepressant

47 (21.3)

 Mood stabiliser

25 (11.3)

  1. aOne patient was confirmed to be either in employment or education; however, this was not further specified; bPatients recorded their own assessment of their overall health status on a scale of 0 (worst health) to 100 (best health) [15]; cSeverity of patient’s psychotic condition at a particular time on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients) [16]; dA scale of 1 (absent) to 7 (extreme) [17]; ePatients may have had more than one comorbidity; fPatients may have been taking more than one medication. CGI, Clinical Global Impression; EQ-5D-5L, EuroQoL-5D; PANSS, Positive and Negative Syndrome Scale; PP3M, paliperidone palmitate 3-monthly; SD, standard deviation; VAS, visual analogue scale
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us